Connection

Co-Authors

This is a "connection" page, showing publications co-authored by DAVID WHEELER and JULIE GASTIER-FOSTER.
Connection Strength

1.018
  1. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell. 2021 01 11; 39(1):38-53.e7.
    View in: PubMed
    Score: 0.197
  2. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst. 2021 01 04; 113(1):27-37.
    View in: PubMed
    Score: 0.050
  3. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 2019 11 05; 29(6):1675-1689.e9.
    View in: PubMed
    Score: 0.046
  4. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018 08 09; 174(4):1034-1035.
    View in: PubMed
    Score: 0.042
  5. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 Jun 19; 23(12):3698.
    View in: PubMed
    Score: 0.042
  6. Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep. 2018 06 12; 23(11):3392-3406.
    View in: PubMed
    Score: 0.042
  7. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell. 2018 04 05; 173(2):305-320.e10.
    View in: PubMed
    Score: 0.041
  8. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell. 2018 04 05; 173(2):355-370.e14.
    View in: PubMed
    Score: 0.041
  9. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018 04 05; 173(2):371-385.e18.
    View in: PubMed
    Score: 0.041
  10. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep. 2018 04 03; 23(1):239-254.e6.
    View in: PubMed
    Score: 0.041
  11. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 04 03; 23(1):313-326.e5.
    View in: PubMed
    Score: 0.041
  12. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018 03 28; 6(3):271-281.e7.
    View in: PubMed
    Score: 0.041
  13. A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat Genet. 2017 Oct; 49(10):1487-1494.
    View in: PubMed
    Score: 0.039
  14. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep. 2017 06 27; 19(13):2878-2880.
    View in: PubMed
    Score: 0.039
  15. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clin Cancer Res. 2016 Nov 15; 22(22):5582-5591.
    View in: PubMed
    Score: 0.037
  16. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016 08 08; 30(2):363.
    View in: PubMed
    Score: 0.037
  17. MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours. Nat Commun. 2015 Dec 04; 6:10013.
    View in: PubMed
    Score: 0.035
  18. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14; 374(2):135-45.
    View in: PubMed
    Score: 0.035
  19. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun. 2015 Mar 19; 6:6604.
    View in: PubMed
    Score: 0.033
  20. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell. 2015 Feb 09; 27(2):286-97.
    View in: PubMed
    Score: 0.033
  21. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014 Oct 28; 111(43):15544-9.
    View in: PubMed
    Score: 0.032
  22. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014 Sep 08; 26(3):319-330.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.